July 10 (Reuters) - Resverlogix Corp RVX.TO
* Resverlogix randomizes first patient in Taiwan/China portion of the phase 3 Betonmace clinical trial
* As a result of randomization hepalink is now responsible for first c$1 million payment to Resverlogix
* Co to be eligible to sales-based milestone payments from Hepalink when Apabetalone reaches annual sales milestones in territories
* Each sales-based milestone ranging from $5 million to $90 million Source text for Eikon: ID:nCNWT29qda Further company coverage: RVX.TO